KR101922266B1 - 선택적 글리코시다제 억제제 및 그의 용도 - Google Patents
선택적 글리코시다제 억제제 및 그의 용도 Download PDFInfo
- Publication number
- KR101922266B1 KR101922266B1 KR1020137014710A KR20137014710A KR101922266B1 KR 101922266 B1 KR101922266 B1 KR 101922266B1 KR 1020137014710 A KR1020137014710 A KR 1020137014710A KR 20137014710 A KR20137014710 A KR 20137014710A KR 101922266 B1 KR101922266 B1 KR 101922266B1
- Authority
- KR
- South Korea
- Prior art keywords
- tetrahydro
- thiazole
- diol
- pyrano
- hydroxyethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CN(C)C1S[C@]2O[C@](C*)[C@@](*)[C@@](*)[C@]2N1 Chemical compound CN(C)C1S[C@]2O[C@](C*)[C@@](*)[C@@](*)[C@]2N1 0.000 description 22
- XGXXDFFLNULEGZ-ZFXZZAOISA-N CC(C)(C)OC(N(CC=C)C(S[C@H]1O[C@@H]([C@H]2OCc3ccccc3)C=O)=N[C@@H]1[C@H]2OCc1ccccc1)=O Chemical compound CC(C)(C)OC(N(CC=C)C(S[C@H]1O[C@@H]([C@H]2OCc3ccccc3)C=O)=N[C@@H]1[C@H]2OCc1ccccc1)=O XGXXDFFLNULEGZ-ZFXZZAOISA-N 0.000 description 1
- GGXLETOBKZSDMS-BFSSTPSDSA-N CC(C)(C)OC(N(CCC=C)C(S[C@H]1O[C@@H]2C(C(F)(F)F)O)=N[C@@H]1C1(CC1)[C@@H]2OCc1ccccc1)=O Chemical compound CC(C)(C)OC(N(CCC=C)C(S[C@H]1O[C@@H]2C(C(F)(F)F)O)=N[C@@H]1C1(CC1)[C@@H]2OCc1ccccc1)=O GGXLETOBKZSDMS-BFSSTPSDSA-N 0.000 description 1
- MVAUDRBFUBQVII-MPKFMROPSA-N CC([C@H]([C@H]1O)O[C@@H]2SC(NCCO)=N[C@@H]2[C@H]1O)O Chemical compound CC([C@H]([C@H]1O)O[C@@H]2SC(NCCO)=N[C@@H]2[C@H]1O)O MVAUDRBFUBQVII-MPKFMROPSA-N 0.000 description 1
- PMIYYBQITRECPH-PRJDIBJQSA-N CC1N=C(N(C)C)S[C@H]1OC Chemical compound CC1N=C(N(C)C)S[C@H]1OC PMIYYBQITRECPH-PRJDIBJQSA-N 0.000 description 1
- BASCULYPSMJIDE-QDJMVLKXSA-N CN(C)C(S[C@H]1O[C@H]([C@@H](C(F)(F)F)O)[C@H]2O)=N[C@@H]1[C@H]2O Chemical compound CN(C)C(S[C@H]1O[C@H]([C@@H](C(F)(F)F)O)[C@H]2O)=N[C@@H]1[C@H]2O BASCULYPSMJIDE-QDJMVLKXSA-N 0.000 description 1
- VQLLHLWBVRPNHG-IDKXIYKKSA-N CN(C)C(S[C@H]1O[C@H]([C@@H](C(F)F)O)[C@H]2O)=N[C@@H]1[C@H]2O Chemical compound CN(C)C(S[C@H]1O[C@H]([C@@H](C(F)F)O)[C@H]2O)=N[C@@H]1[C@H]2O VQLLHLWBVRPNHG-IDKXIYKKSA-N 0.000 description 1
- VQLLHLWBVRPNHG-FDEXCMPBSA-N CN(C)C(S[C@H]1O[C@H]([C@H](C(F)F)O)[C@H]2O)=NC1[C@H]2O Chemical compound CN(C)C(S[C@H]1O[C@H]([C@H](C(F)F)O)[C@H]2O)=NC1[C@H]2O VQLLHLWBVRPNHG-FDEXCMPBSA-N 0.000 description 1
- QCQKKKQVWWMBCD-BFZMXELVSA-N C[C@H]([C@@H]([C@H](CO)O)/N=C(\C)/N(C)C)OCC(C)(C)F Chemical compound C[C@H]([C@@H]([C@H](CO)O)/N=C(\C)/N(C)C)OCC(C)(C)F QCQKKKQVWWMBCD-BFZMXELVSA-N 0.000 description 1
- PMIYYBQITRECPH-PHDIDXHHSA-N C[C@H]1N=C(N(C)C)S[C@H]1OC Chemical compound C[C@H]1N=C(N(C)C)S[C@H]1OC PMIYYBQITRECPH-PHDIDXHHSA-N 0.000 description 1
- KFXPRXXTEPSSOD-FMDGEEDCSA-N OC[C@H]([C@H]1O)O[C@@H]2SC(NCCF)=N[C@@H]2[C@H]1O Chemical compound OC[C@H]([C@H]1O)O[C@@H]2SC(NCCF)=N[C@@H]2[C@H]1O KFXPRXXTEPSSOD-FMDGEEDCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2010/078528 WO2012061972A1 (en) | 2010-11-08 | 2010-11-08 | Selective glycosidase inhibitors and uses thereof |
| CNPCT/CN2010/078528 | 2010-11-08 | ||
| US41859610P | 2010-12-01 | 2010-12-01 | |
| US61/418,596 | 2010-12-01 | ||
| PCT/CN2011/080691 WO2012062157A1 (en) | 2010-11-08 | 2011-10-12 | Pyrano[3,2-d]thiazol derivatives and uses thereof as selective glycosidase inhibitors |
| CNPCT/CN2011/080691 | 2011-10-12 | ||
| PCT/US2011/059668 WO2012064680A1 (en) | 2010-11-08 | 2011-11-08 | Selective glycosidase inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130129974A KR20130129974A (ko) | 2013-11-29 |
| KR101922266B1 true KR101922266B1 (ko) | 2018-11-26 |
Family
ID=46051261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137014710A Expired - Fee Related KR101922266B1 (ko) | 2010-11-08 | 2011-11-08 | 선택적 글리코시다제 억제제 및 그의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2637503B1 (https=) |
| JP (1) | JP5965407B2 (https=) |
| KR (1) | KR101922266B1 (https=) |
| AR (1) | AR083798A1 (https=) |
| AU (2) | AU2011326186A1 (https=) |
| BR (1) | BR112013011441B8 (https=) |
| CA (1) | CA2816798C (https=) |
| ES (1) | ES2600028T3 (https=) |
| MX (1) | MX336611B (https=) |
| RU (1) | RU2592285C2 (https=) |
| TW (1) | TW201249848A (https=) |
| WO (1) | WO2012064680A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2321289A4 (en) | 2008-08-01 | 2011-11-16 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE HEMMER AND ITS USE |
| WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US8933040B2 (en) | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
| RU2609210C2 (ru) * | 2010-12-23 | 2017-01-31 | Алектос Терапьютикс Инк. | Селективные ингибиторы гликозидазы и их применение |
| EP2688899B1 (en) | 2011-03-24 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2691407B1 (en) | 2011-03-31 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2726468B1 (en) | 2011-06-27 | 2017-04-12 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013033098B8 (pt) | 2011-06-27 | 2021-03-23 | Alectos Therapeutics Inc | inibidores de glicosidade seletivos e usos dos mesmos |
| EP2847199B1 (en) * | 2012-05-08 | 2017-10-25 | Merck Sharp & Dohme Corp. | Permeable glycosidase inhibitors and uses thereof |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| KR20150079711A (ko) * | 2012-10-31 | 2015-07-08 | 알렉토스 테라퓨틱스 인크. | 글리코시다아제 저해제 및 이의 용도 |
| WO2014100934A1 (en) * | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| RU2748383C1 (ru) * | 2020-10-21 | 2021-05-25 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Способ терапии болезни Тея-Сакса и болезни Сандхоффа с помощью генетически модифицированных мезенхимных стволовых клеток человека со сверхэкспрессией β-гексозаминидазы A |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100016386A1 (en) | 2006-08-31 | 2010-01-21 | David Vocadlo | Selective glycosidase inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1441749A1 (ru) * | 1987-03-16 | 1996-01-10 | Институт Тонкой Органической Химии Им.А.Л.Мнджояна | 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ |
| CA2599843C (en) | 2005-03-01 | 2013-08-27 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| EP2321289A4 (en) | 2008-08-01 | 2011-11-16 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE HEMMER AND ITS USE |
| CA2732335A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| CA2737267A1 (en) | 2008-09-16 | 2010-04-08 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| ES2568603T3 (es) * | 2011-08-25 | 2016-05-03 | Merck Patent Gmbh | Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasas |
-
2011
- 2011-11-07 TW TW100140566A patent/TW201249848A/zh unknown
- 2011-11-08 AR ARP110104166A patent/AR083798A1/es unknown
- 2011-11-08 CA CA2816798A patent/CA2816798C/en active Active
- 2011-11-08 AU AU2011326186A patent/AU2011326186A1/en not_active Abandoned
- 2011-11-08 EP EP11840448.2A patent/EP2637503B1/en active Active
- 2011-11-08 ES ES11840448.2T patent/ES2600028T3/es active Active
- 2011-11-08 RU RU2013126531/04A patent/RU2592285C2/ru active
- 2011-11-08 MX MX2013005118A patent/MX336611B/es unknown
- 2011-11-08 JP JP2013537923A patent/JP5965407B2/ja not_active Expired - Fee Related
- 2011-11-08 KR KR1020137014710A patent/KR101922266B1/ko not_active Expired - Fee Related
- 2011-11-08 BR BR112013011441A patent/BR112013011441B8/pt not_active IP Right Cessation
- 2011-11-08 WO PCT/US2011/059668 patent/WO2012064680A1/en not_active Ceased
-
2016
- 2016-04-07 AU AU2016202186A patent/AU2016202186B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100016386A1 (en) | 2006-08-31 | 2010-01-21 | David Vocadlo | Selective glycosidase inhibitors and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| The EMBO Journal, 25(7), 1569-1570, 2006. |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013126531A (ru) | 2014-12-20 |
| MX336611B (es) | 2016-01-22 |
| JP2013541596A (ja) | 2013-11-14 |
| TW201249848A (en) | 2012-12-16 |
| AU2011326186A8 (en) | 2013-08-01 |
| ES2600028T3 (es) | 2017-02-06 |
| BR112013011441B1 (pt) | 2021-11-09 |
| EP2637503B1 (en) | 2016-09-14 |
| BR112013011441B8 (pt) | 2023-04-18 |
| CA2816798A1 (en) | 2012-05-18 |
| CA2816798C (en) | 2019-02-26 |
| AU2011326186A1 (en) | 2013-05-23 |
| KR20130129974A (ko) | 2013-11-29 |
| JP5965407B2 (ja) | 2016-08-03 |
| EP2637503A1 (en) | 2013-09-18 |
| BR112013011441A2 (pt) | 2016-07-19 |
| RU2592285C2 (ru) | 2016-07-20 |
| MX2013005118A (es) | 2013-07-29 |
| WO2012064680A1 (en) | 2012-05-18 |
| AU2016202186A1 (en) | 2016-04-28 |
| EP2637503A4 (en) | 2014-04-09 |
| AU2016202186B2 (en) | 2017-10-12 |
| AR083798A1 (es) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101922266B1 (ko) | 선택적 글리코시다제 억제제 및 그의 용도 | |
| JP5861194B2 (ja) | 選択的グルコシダーゼインヒビターおよびその使用 | |
| JP6147737B2 (ja) | 選択的グリコシダーゼ阻害剤およびその使用 | |
| RU2672873C2 (ru) | Ингибиторы гликозидаз и их применения | |
| JP5687194B2 (ja) | 選択的グリコシダーゼインヒビターおよびその使用 | |
| WO2012062157A1 (en) | Pyrano[3,2-d]thiazol derivatives and uses thereof as selective glycosidase inhibitors | |
| EP2726492B1 (en) | Selective glycosidase inhibitors and uses thereof | |
| WO2014032187A1 (en) | Glycosidase inhibitors and uses thereof | |
| WO2014032184A1 (en) | Glycosidase inhibitors and uses thereof | |
| WO2012061927A1 (en) | Selective glycosidase inhibitors and uses thereof | |
| WO2014100934A1 (en) | Glycosidase inhibitors and uses thereof | |
| EP2890675A1 (en) | Glycosidase inhibitors and uses thereof | |
| WO2012126091A1 (en) | Selective glycosidase inhibitors and uses thereof | |
| US8901087B2 (en) | Selective glycosidase inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-5-5-R10-R17-oth-X000 |
|
| FPAY | Annual fee payment |
Payment date: 20210929 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R14-asn-PN2301 |
|
| FPAY | Annual fee payment |
Payment date: 20220921 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20241121 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE Effective date: 20241121 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20241121 |